Current Report Filing (8-k)
13 7월 2022 - 7:01PM
Edgar (US Regulatory)
0001626644
false
0001626644
2022-07-12
2022-07-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
U.S. SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): July
12, 2022
ODYSSEY
HEALTH, INC.
(Exact name of small business
issuer as specified in its charter)
| Nevada |
000-56196 |
47-1022125 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer ID No.) |
2300
West Sahara Avenue, Suite 800 - #4012,
Las
Vegas, NV |
89102 |
| (Address of principal executive offices) |
(Zip Code) |
(702) 780-6559
(Issuer’s
Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| N/A |
N/A |
N/A |
Securities registered pursuant
to Section 12(g) of the Act:
| Title of each Class |
Trading Symbol |
Name of Each Exchange on Which Registered |
| Common Stock ($0.001 par value) |
ODYY |
OTC |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Material Event |
On July 12, 2022, Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey
Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion
of all three cohorts in their Phase I Single Ascending Dosing clinical trial. Odyssey’s trial involves administering PRV-002, the
Company’s novel drug to treat concussion, to healthy human subjects.
| Item 7.01 | Regulation FD Disclosure |
Attached is a copy of a press release being issued by the Company relating
to the above-referenced matter, a copy of which is attached as Exhibit as 99.1 and is hereby incorporated.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
| Number |
Exhibit |
| 99.1 |
Press Release |
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Odyssey Group International,
Inc. |
| |
|
| |
By: |
/s/ Joseph Michael Redmond |
| |
|
Joseph Michael Redmond
Chief Executive Officer |
Date:
July 13, 2022
Odyssey (QB) (USOTC:ODYY)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Odyssey (QB) (USOTC:ODYY)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
